NCT03315364 2026-04-01OPTIMALDaehwa Pharmaceutical Co., Ltd.Phase 2/3 Active not recruiting549 enrolled
NCT05537740 2026-03-20A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsBayerPhase 1 Active not recruiting129 enrolled
NCT03742245 2026-03-16Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerThe Methodist Hospital Research InstitutePhase 1 Active not recruiting28 enrolled
NCT06105632 2026-02-13A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentPfizerPhase 2 Active not recruiting333 enrolled
NCT01552434 2025-10-14Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseM.D. Anderson Cancer CenterPhase 1 Active not recruiting155 enrolled
NCT06570031 2025-07-02ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerOno Pharmaceutical Co. LtdPhase 1 Active not recruiting46 enrolled
NCT02804815 2025-06-10Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid TumoursUniversity College, LondonPhase 3 Active not recruiting11,000 enrolled
NCT03075072 2024-10-23Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized TrialDana-Farber Cancer InstitutePhase NA Active not recruiting196 enrolled